The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

Meningococcal infections can lead to severe, sometimes deadly, bloodstream infections, and severe swelling in the brain and ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

Recent health news highlights US FDA's hold on Moderna's norovirus vaccine trial due to a side-effect case, Robert F. Kennedy ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines, the company ...

GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.